Cars.com
CARS
Lantheus
LNTH
Halozyme Therapeutics
HALO
DOMINOS PIZZA ENTERPRISES LIMITED UNSP ADR EACH REPR 0.5 ORD SHS
DMZPY
Collegium Pharmaceutical
COLL
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 13.45%91.47M | -169.39%-41.46M | 309.08%190.34M | -302.02%-19.32M | -82.74%-38.09M | 1,385.63%80.63M | 80.21%59.75M | 34,062.77%46.53M | 54.60%-4.81M | -22.59%-20.85M |
Net income from continuing operations | 133.85%2.9M | -1,335.35%-15.9M | 265.46%38.9M | 17.44%-13.88M | -68.80%-6.22M | 78.23%-8.57M | 213.99%1.29M | 349.13%10.64M | 29.35%-16.81M | 63.71%-3.68M |
Depreciation and amortization | 10.14%17.36M | 16.64%4.65M | 8.93%4.25M | 1.42%4.2M | 14.15%4.26M | 28.12%15.76M | 27.97%3.99M | 14.58%3.9M | 39.70%4.15M | 32.45%3.73M |
Deferred tax | -12,313.89%-8.79M | -326.65%-2.19M | -1,680.45%-5.56M | -1,216.67%-402K | -3.71%-643K | 104.22%72K | 181.96%968K | 26.76%-312K | 175.00%36K | -1,069.81%-620K |
Other non cash items | -149.09%-1.21M | -183.42%-1.23M | 26.09%261K | -149.74%-95K | -124.37%-144K | 474.92%2.47M | 200.82%1.48M | -85.62%207K | 126.75%191K | 612.05%591K |
Change In working capital | -39.04%16.36M | -211.61%-44.42M | 556.74%136.91M | -509.84%-25.96M | -69.79%-50.17M | 506.46%26.84M | 53.37%39.8M | 336.31%20.85M | -269.20%-4.26M | -94.18%-29.55M |
-Change in receivables | 123.57%13.78M | 216.91%40.25M | -42.18%-51.14M | 25.98%-14.28M | 24.66%38.95M | -76.23%-58.45M | -40.79%-34.43M | -188.09%-35.97M | -241.61%-19.29M | 231.59%31.25M |
-Change in prepaid assets | -24.37%-5.32M | 624.51%1.86M | 21.19%-2.76M | -3,010.89%-6.28M | 325.00%1.86M | 62.19%-4.28M | 107.05%257K | 12.28%-3.51M | 94.87%-202K | -416.03%-828K |
-Change in payables and accrued expense | -88.97%10.17M | -215.90%-85.59M | 216.92%188.69M | -122.18%-3.62M | -55.13%-89.3M | 65.49%92.16M | 33.96%73.85M | 624.65%59.54M | 32.46%16.34M | -187.97%-57.56M |
-Change in other current liabilities | 5.27%-1.64M | -63.76%-619K | -11.04%-342K | -108.07%-335K | 61.36%-340K | 72.94%-1.73M | 73.23%-378K | -196.86%-308K | 57.52%-161K | 82.07%-880K |
-Change in other working capital | 27.67%-630K | -163.98%-318K | 125.84%2.47M | -53.26%-1.44M | 11.60%-1.35M | -117.75%-871K | 50.61%497K | 225.43%1.1M | -733.11%-937K | -30,420.00%-1.53M |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 13.45%91.47M | -169.39%-41.46M | 309.08%190.34M | -302.02%-19.32M | -82.74%-38.09M | 1,385.63%80.63M | 80.21%59.75M | 34,062.77%46.53M | 54.60%-4.81M | -22.59%-20.85M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | -456.52%-215.8M | 69.70%-10.21M | -8,815.30%-143.36M | -3,616.03%-60.72M | 18.12%-1.51M | -57.23%-38.78M | -1,504.86%-33.69M | 91.51%-1.61M | 29.75%-1.63M | -41.47%-1.85M |
Net PPE purchase and sale | 8.42%-924K | -53.03%-101K | 19.49%-219K | -83.68%-349K | 46.99%-255K | 25.42%-1.01M | 77.55%-66K | 13.38%-272K | 70.45%-190K | -371.57%-481K |
Net intangibles purchase and sale | -6.25%-5.32M | 14.02%-736K | 4.42%-1.28M | -41.62%-2.05M | 7.97%-1.26M | 12.47%-5M | 46.10%-856K | -7.66%-1.34M | 14.20%-1.44M | -13.53%-1.37M |
Net business purchase and sale | -38.05%-45.23M | 100.63%208K | ---- | ---- | ---- | -86.23%-32.76M | -14,998.62%-32.76M | ---- | ---- | ---- |
Net investment purchase and sale | ---164.33M | ---9.58M | ---96.42M | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | -456.52%-215.8M | 69.70%-10.21M | -8,815.30%-143.36M | -3,616.03%-60.72M | 18.12%-1.51M | -57.23%-38.78M | -1,504.86%-33.69M | 91.51%-1.61M | 29.75%-1.63M | -41.47%-1.85M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -114.29%-37.63M | -189.78%-21.03M | -107.72%-20.46M | -58.72%1.61M | 24.88%2.25M | 1,198.95%263.42M | 70.47%-7.26M | 10,977.51%264.97M | 219.15%3.9M | 159.93%1.8M |
Net issuance payments of debt | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Net common stock issuance | -116.75%-43.74M | ---20.86M | ---- | ---- | ---- | --261.12M | --0 | ---- | ---- | ---- |
Proceeds from stock option exercised by employees | -33.18%8.72M | -9.99%1.66M | -43.70%2.42M | -58.72%1.61M | 0.80%3.03M | 58.50%13.05M | 5.74%1.84M | 2.43%4.3M | 219.15%3.9M | 180.86%3.01M |
Net other financing activities | 75.71%-2.61M | 79.90%-1.83M | --0 | --0 | 35.13%-783K | -71.62%-10.75M | -2,287.93%-9.1M | 75.28%-447K | --0 | 70.39%-1.21M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -114.29%-37.63M | -189.78%-21.03M | -107.72%-20.46M | -58.72%1.61M | 24.88%2.25M | 1,198.95%263.42M | 70.47%-7.26M | 10,977.51%264.97M | 219.15%3.9M | 159.93%1.8M |
Net cash flow | ||||||||||
Beginning cash position | 86.40%654.61M | -11.46%565.04M | 64.39%539.3M | 88.10%619.01M | 86.40%654.61M | -9.81%351.18M | 81.71%638.21M | -9.52%328.06M | -11.00%329.08M | -9.81%351.18M |
Current changes in cash | -153.06%-161.96M | -486.58%-72.7M | -91.44%26.52M | -2,987.83%-78.43M | -78.80%-37.36M | 806.54%305.27M | 190.34%18.81M | 1,958.33%309.9M | 78.27%-2.54M | 1.98%-20.89M |
Effect of exchange rate changes | 241.53%2.6M | 220.86%2.9M | -418.62%-787K | -184.30%-1.28M | 246.76%1.76M | -136.53%-1.84M | 63.22%-2.4M | -95.36%247K | -66.39%1.52M | -170.62%-1.2M |
End cash Position | -24.35%495.24M | -24.35%495.24M | -11.46%565.04M | 64.39%539.3M | 88.10%619.01M | 86.40%654.61M | 86.40%654.61M | 81.71%638.21M | -9.52%328.06M | -11.00%329.08M |
Free cash flow | 14.23%85.23M | -171.90%-42.3M | 320.39%188.85M | -237.19%-21.72M | -74.52%-39.61M | 4,641.21%74.61M | 88.10%58.83M | 2,754.91%44.92M | 50.12%-6.44M | -23.94%-22.7M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |